Arovella Newsletter July 2022
Hello again and welcome to our latest review of what’s been happening with your company. Before we lead you to the updates on our development, I will briefly acknowledge the elephant in the room. It of course being the current state of the market and the fall-off in the biotech sector.
That said, I am firmly of the belief that this contrary evaluation of our sector of business is more a reflection of kneejerk reaction to worldwide economic and political concerns than criticism of the remarkable achievements in science that occur every day. What heartens me is that I know for every naysayer out there – there is a shrewd investor, you, who will see advantage rather than liability and invest in companies such as ours. Cast a slide rule over us and you will see our position languishing in the market but developing to expectation in our science. Truly developing. No backward steps. We are enthusiastic and committed to bringing our therapies to cancer patients across the country and across the world. Our partnerships with internationally acclaimed cancer research bodies such as Imperial College London and MD Anderson Cancer Center in Houston, are showing great promise and speak volumes as to the viability and credibility of what we do.
So, enough said on the doom and gloom factor. We’re all systems go!
Dr. Michael Baker
CEO AND MD
